Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Neurodermatitis, Rash pruritic, Urticaria
Clinical narrative: Infection of the hair follicles or a severe eczema; infection of the hair follicles; Nodular periego; Positive for copper sulfate; Itchy rash; Little bumps on her left shin bone; First Dose on 19-Jan-2021 and second dose on 26-Feb-2021; This spontaneous case was reported by a patient and describes the occurrence of FOLLICULAR ECZEMA (Infection of the hair follicles or a severe eczema), HAIR DISORDER (infection of the hair follicles), NEURODERMATITIS (Nodular periego), ALLERGY TO METALS (Positive for copper sulfate) and RASH PRURITIC (Itchy rash) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 066H21A, 001A20A and 041L20A) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     The patient was not received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  The patient's past medical history included Knee replacement (in that left knee).   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 26-Feb-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First Dose on 19-Jan-2021 and second dose on 26-Feb-2021). In January 2022, the patient experienced URTICARIA (Little bumps on her left shin bone). On an unknown date, the patient experienced FOLLICULAR ECZEMA (Infection of the hair follicles or a severe eczema), HAIR DISORDER (infection of the hair follicles), NEURODERMATITIS (Nodular periego), ALLERGY TO METALS (Positive for copper sulfate) and RASH PRURITIC (Itchy rash). The patient was treated with CORTISONE at an unspecified dose and frequency; LORATADINE (CLARITINO) at an unspecified dose and frequency; CETIRIZINE HYDROCHLORIDE (ZYRTEC R) at an unspecified dose and frequency and FAMOTIDINE (PEPCIDINE) at an unspecified dose and frequency. At the time of the report, FOLLICULAR ECZEMA (Infection of the hair follicles or a severe eczema), HAIR DISORDER (infection of the hair follicles), ALLERGY TO METALS (Positive for copper sulfate), RASH PRURITIC (Itchy rash) and URTICARIA (Little bumps on her left shin bone) had not resolved and NEURODERMATITIS (Nodular periego) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First Dose on 19-Jan-2021 and second dose on 26-Feb-2021) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Allergy test: (Positive) copper sulfate.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication was not provided. It was reported that patient had lab test included Tryptase increased and Histamine level increased ,these result was inconclusive. Treatment medication include dupexant.